---

TCON stock forecast

Our latest prediction for TRACON Pharmaceuticals Inc's stock price was made on the Nov. 7, 2022 when the stock price was at 1.52$.

In the short term (2weeks), TCON's stock price should underperform the market by -3.36%. During that period the price should oscillate between -10.76% and +6.48%.

In the medium term (3months), TCON's stock price should outperform the market by 26.60%. During that period the price should oscillate between -31.40% and +41.86%.

Get email alerts

Create a solid portfolio with TCON

Add TCON to your portfolio and optimize it!

---

About TRACON Pharmaceuticals Inc

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company's clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.

At the moment the company generates 10M USD in revenues.

On its last earning announcement, the company reported a loss of None$ per share.

The book value per share is 1.24$

TRACON Pharmaceuticals Inc website